TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
TuHURA生物科技與kintara therapeutics宣佈達成協議，可能收購Kineta的抗VISTA抗體。
- KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies
- KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors
- To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined
- Concurrent $5 million investment from existing TuHURA shareholder preserves TuHURA's strong balance sheet for advancing its IFx-2.0 Phase 3 accelerated approval trial and novel bi-functional ADCs
- KVA12123是一種有理靶向的抗VISTA抗體檢查點抑制劑，用於扭轉VISTA免疫抑制並重塑腫瘤微環境（TME），以克服對於免疫療法的獲得性耐藥性
- KVA12123目前正在一項1/2期臨床研究中作爲單一治療方法和與默沙東的抗PD1療法KEYTRUDA（pembrolizumab）聯合用於晚期實體瘤患者。
- 到目前爲止，KVA12123已經證明了良好的臨床安全性和耐受性，觀察到沒有劑量限制的毒性和無細胞因子釋放綜合徵（CRS）相關毒性
- 現有的TuHURA股東同時進行500萬美元的投資，保持強大的資產負債表，推進其IFx-2.0 3期快速批准試驗和新型雙重嵌合物ADCs（抗體藥物複合物）的研發。